Fenticonazole nitrate/lidocaine/tinidazole
| Combination of | |
|---|---|
| Fenticonazole nitrate | Antifungal |
| Lidocaine | Local anesthetic |
| Tinidazole | Antibiotic |
| Clinical data | |
| Trade names | Evegyn |
| Routes of administration | Vaginal[1][2] |
Fenticonazole nitrate/lidocaine/tinidazole, tentative brand name Evegyn, is a combination of the antibiotic tinidazole, the antifungal fenticonazole, and the local anesthetic lidocaine which is under development for the treatment of bacterial vaginosis, vulvovaginal candidiasis, and vaginitis.[1][3][2] It is taken by vaginal administration.[1][2] The drug is being developed by Exeltis Turkey and is being developed towards approval specifically in Turkey.[1][3][2] As of February 2025, it is in phase 3 clinical trials for all indications.[1][3][2]
References
[edit]- ^ a b c d e "Fenticonazole nitrate/lidocaine/tinidazole". AdisInsight. 19 February 2025. Retrieved 26 February 2025.
- ^ a b c d e Tavmergen E, Acet F, Bahat PY, Karadağ B, Yaşar L, Kale A, et al. (5 June 2024). "Phase III Study to Evaluate the Efficacy and Safety of Two Novel Fixed-Dose Vaginal Ovule Formulations in the Treatment of Various Vaginal Infections: One-Shot Study Running Title: Phase III study of two novel vaginal ovules" (PDF). Archives of Gynaecology and Women Health. 3 (2). doi:10.58489/2836-497X/024. Retrieved 26 February 2025.
- ^ a b c "Delving into the Latest Updates on Fenticonazole nitrate/lidocaine/tinidazole with Synapse". Synapse. 23 January 2025. Retrieved 26 February 2025.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |